Brief: Virios Therapeutics On May 24, Got Letter From Nasdaq Stating Co Had Regained Compliance With Minimum Bid Price Requirement Of Nasdaq Listing Rule
25/05/2023 13:34
May 25 (Reuters) - Virios Therapeutics Inc VIRI.O :
* VIRIOS THERAPEUTICS: ON MAY 24, GOT LETTER FROM NASDAQ
STATING
CO HAD REGAINED COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT OF
NASDAQ LISTING RULE
Source text for Eikon: ID:
Further company coverage: VIRI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study